CORRESP 1 filename1.htm CORRESP

VOR BIOPHARMA INC.

100 Cambridgepark Drive, Suite 101

Cambridge, MA 02140

January 27, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Alan Campbell

 

Re:    Vor Biopharma Inc.
   Registration Statement on Form S-3 (File No. 333-284380)
   Request for Acceleration of Effective Date
     Requested Date:    January 29, 2025
     Requested Time:  4:00 p.m. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-284380) (theRegistration Statement”) to become effective on January 29, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043, or in her absence, Divakar Gupta at (212) 479-6474.

 

Very truly yours,
Vor Biopharma Inc.
By:  

/s/ Robert Ang

  Robert Ang
  Chief Executive Officer